Business Wire

Polpharma Biologics Announces Rebrand and Launch of New Value “We Care” as 2000 L Bioreactors Begin Validation at Its Warsaw Site

Share

European biotechnology company Polpharma Biologics has unveiled a new logo and corporate message as part of an extensive rebranding initiative.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005383/en/

Dr Joerg Windisch, CEO of Polpharma Biologics, said “Our new brand represents our passion and dedication to innovation, we utilize the latest technology and cutting-edge techniques to discover and advance ground breaking biologics to the clinic, whether this is our own pipeline or that of our partners.

The industry is rapidly reducing the time to develop and manufacture new molecules, this is down to significant improvements in automation with many previously time consuming steps replaced with equipment that can analyze thousands of samples in minutes incredibly accurately. Throughout our entire process from early stage discovery, through cell line development and process development and to fill finish we have adopted the very latest technology to ensure we can offer the best timelines and most comprehensive analytics to generate the highest quality biologic drugs, our new brand represents our commitment to this innovation.”

Dr Windisch, continued “We are also launching our new value proposition, “We Care”, this represents our unwavering dedication to the patients that need our products and our commitment to honesty and transparency in all our interactions. All our colleagues carry these values through all the work they do and in all our cooperation with partners. We all share the same goal – delivering safe and effective medicines to patients.”

The new brand and values launch come after a year of significant growth at Polpharma Biologics, it has brought its Utrecht research and development site, formerly Bioceros, and its Warsaw manufacturing site under the Polpharma Biologics brand, and significantly expanded its workforce by over 250 employees.

Much of the new recruitment has taken place at their new clinical and commercial manufacturing site in Warsaw, which began construction in 2018. It has reached a significant milestone with the installation of its first bioreactor suite which contains twin 2000 L SUBs. The suite is now under validation and will be suitable for the manufacture of clinical and commercial mammalian products, it is expected to be ready for its first production run in mid-2021. This is one of 5 manufacturing suites currently planned for the site which also contains research and process development laboratories.

Frank Ternes, Global Head of CDMO commented “The combination of our new brand and installation of new bioreactors brings us closer to our ambition to be an industry-leading biotechnology company, with a world-class offering to help partners take their products rapidly to market with the maximum chance of success. Polpharma Biologics now has the ability to offer a full range of solutions for both mammalian and microbial from discovery to commercial supply for both drug substance and drug product.”

-ENDS-

About Polpharma Biologics

Polpharma Biologics is a European biopharmaceutical company focused on the development and manufacture of biosimilar and novel biologic drugs. Polpharma Biologics operates across centers of excellence in Poland and the Netherlands providing fully integrated solutions along the biopharmaceutical value chain. Polpharma Biologics offers antibody discovery and optimization, cell line development, product and process development and clinical and commercial scale manufacturing to support the development of its proprietary portfolio of products and the provision of high quality contract development and manufacturing services to industry partners around the globe.

Contact information

Joseph Reeds
Head of Marketing, Polpharma Biologics
Joseph.reeds@polpharmabiologics.com
+447807832776

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BORN Expands With Alkeon B2B Market Network Platform Transforming Commercial Models, Starting With the Trade Show Industry2.3.2021 15:12:00 CETPress release

BORN, announces the expansion of innovative B2B subsidiary Alkeon, the world's first global SaaS market-network combining content, community, and commerce to connect buyers and sellers through a best-in-class platform, powered by machine learning. The 2020 pandemic generated a tremendous and immediate need for companies of all categories to pivot at a moment’s notice, with over 10,000 global trade shows completely upended due to cancellations of physical events. BORN, a purpose driven lifestyle company dedicated to reimagining the discovery, transaction and connection of the B2B and B2C communities, found an opportune moment to quickly scale and enhance their technology solutions. The company formally established Alkeon, an enterprise dedicated to supporting the needs of companies who are adapting to the current and future landscapes and need the right partner to support them through the process. Combining aesthetic and function to create designed technology, Alkeon is a market-network

South Africa and France Lead the Way in Public and Private Sector Gender Diversity, Latest Research by Kearney Reveals2.3.2021 15:00:00 CETPress release

The latest ‘Gender Equality Report’ from Kearney has revealed progress in the representation of women in both public and private sectors, but the figures still don’t show parity. Ahead of International Women’s Day, the analysis provides insight into the progress of gender diversity in private and public sectors across nine countries – the United States, United Kingdom, Australia, India, France, Spain, Germany, South Africa and Singapore. The annual report revealed that France was number one for representation in the private sector with women comprising nearly 44% (43.8%) of board members on average, however only 2% of these women held top board positions. The UK (36%) and Australia (34%) also scored highly for representation of women on boards. The average for board level representation of women is 29.9% - not even one in three. % Female board level representation by country France 43.8% UK 36.0% Australia 34.0% Germany 32.5% Spain 29.8% US 29.8% South Africa 28.5% Singapore 17.3% Indi

beqom Announces beqom FlexFS, a Compensation Management Solution Dedicated to Financial Services2.3.2021 15:00:00 CETPress release

beqom, provider of cloud-based compensation management software, today announced the launch of beqom FlexFS, a solution designed specifically for the financial services (FS) industry. “Financial services compensation is unique,” says Vismay Gada, Head of North America and Global Financial Services at beqom. “First there is a broad spectrum of financial services companies—retail banking, investment banking, asset management, hedge funds, insurance, private equity, and so on. That means that rewards and deferred compensation structures have many specialized needs across the industry. And, companies in each segment have to deal with different regulations that impact compensation treatment, which has its own unique challenges. Our FS customers have come to us to help them address complex compensation requirements that are beyond the scope of what their core HR systems can handle.” “We usually see a lot of our FS companies use Excel or Access databases to augment the limitations of core HR

Craig Lipset is Appointed Chairman of the Trialbee Industry Advisory Board2.3.2021 15:00:00 CETPress release

Trialbee, the leading global data and technology platform provider for patient matching and enrollment in clinical trials, today announced the appointment of Craig Lipset as Chairman of the Trialbee Industry Advisory Board. Craig is a recognized visionary leader who has spent his career dedicated to transforming some of the most challenging issues in clinical research through new innovations. Craig is the former Head of Clinical Innovation and Venture Partner at Pfizer and a distinguished leader at the forefront of innovation in clinical research and medicine development. Most recently Craig cofounded and co-Chairs the Decentralized Trials & Research Alliance (DTRA), which roughly 100 leading life science organizations have joined the first few months since it was established. The core mission of DTRA is making clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research. A significant barrier to patien

Maana and Aramco Trading Company Launch AI Application to Optimize Maritime Fleet and Shipping Operations2.3.2021 15:00:00 CETPress release

Aramco Trading Company (ATC) and Maana today announced the launch of Fanar, the first Artificial Intelligence (AI)-driven maritime fleet optimization application on Microsoft Azure purpose-built for the oil and gas industry. Fanar combines the expertise of ATC and the Maana Q knowledge technology. It unifies maritime fleet optimization, planning, management and shipment scheduling on a single platform. The application: systematically integrates all data sources, constraints, and business rules automatically optimizes schedules across the fleet with a single click rapidly processes “what if” scenarios for better insights dynamically incorporates historic performance to generate new predictions Fanar has been tested daily by ATC since June 2020. “Collaboration between Maana and Microsoft helps us, through Fanar, to drive down costs,” said Ibrahim Q. Al Buainain, President and CEO of Aramco Trading Company. “Fanar enables us to optimize all local decisions across our maritime shipping and

PierianDx Announces the Appointment of Lindsay Mateo as Chief Business Officer2.3.2021 15:00:00 CETPress release

PierianDx, the global leader in clinical genomics knowledge, today announced the appointment of Lindsay Mateo as Chief Business Officer, effective immediately. In her new role, Ms. Mateo will reinforce the company’s position as the leading provider of clinical genomics solutions in the fight against cancer and hereditary disease. She will also head the company’s life sciences efforts, establishing key alliances with industry partners and biopharmaceutical companies that will ultimately provide broader access to genomic testing and precision medicine-based treatments for patients. Ms. Mateo is an experienced executive with a history of building world-class teams, devising successful commercial strategies, and building partnerships within the diagnostics industry. Prior to joining PierianDx, she served as Head of Commercial Operations and later as VP, Head of Life Sciences at Tempus. She has also led commercial teams at NAVICAN, an Intermountain Healthcare Company, focused on precision m

Kymeta and Blue Edge Global Strategic Partnership Delivers Real World SATCOM Field Training with Military Trained Specialists2.3.2021 15:00:00 CETPress release

Kymeta (www.kymetacorp.com), the communications company making mobile global, announced today a new premier training partnership with Blue Edge Global, a privately owned and operated, certified Service-Disabled Veteran Owned Small Business. The partnership is designed to provide instructor-led responsive training solutions for land, air, sea, and space domains where uninterrupted communications are required to enable high risk missions, first responder arrive-ready solutions and where natural or other disasters require immediate logistical support. Together, Kymeta and Blue Edge Global will offer downrange training with a team of military SATCOM specialists to the Department of Defense (DoD), Ministry of Defense (MoD) and Emergency Services teams globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005134/en/ Military specialist attends advanced SATCOM training. (Photo: Business Wire) The collaboration with Blue Ed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom